-transparent.png){kind=logo}
A double-blind, parallel group, placebo-controlled study was carried out in 30 elderly patients with moderate to severe mental deterioration to assess the effect of suloctidil on their mental condition. A battery of clinical and psychometric evaluations failed to demonstrate any significant differences between the two groups at the end of a 6-month treatment period during which patients received either 200 mg suloctidil or placebo 3-times daily. However, further analysis of the results showed that in the sub-group of patients with moderate mental deterioration on entry, suloctidil treatment produced significant improvement from baseline in the Rey 15 words test and the results were significantly different from those in patients with severe mental deterioration. No consistent changes were observed in the placebo group.
F Baro, and
M Malfroid, and
T Waegemans, and
J P Cox
January 1982,
The British journal of surgery,
F Baro, and
M Malfroid, and
T Waegemans, and
J P Cox
December 1983,
Epilepsia,
F Baro, and
M Malfroid, and
T Waegemans, and
J P Cox
July 2006,
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
F Baro, and
M Malfroid, and
T Waegemans, and
J P Cox
January 2018,
The lancet. Gastroenterology & hepatology,
F Baro, and
M Malfroid, and
T Waegemans, and
J P Cox
July 2005,
Journal of the American Academy of Dermatology,
F Baro, and
M Malfroid, and
T Waegemans, and
J P Cox
October 1984,
Epilepsia,
F Baro, and
M Malfroid, and
T Waegemans, and
J P Cox
October 1989,
Gut,
F Baro, and
M Malfroid, and
T Waegemans, and
J P Cox
August 2012,
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
F Baro, and
M Malfroid, and
T Waegemans, and
J P Cox
July 2013,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
F Baro, and
M Malfroid, and
T Waegemans, and
J P Cox
February 1977,
Acta psychiatrica Scandinavica,
